Sign in

CIK 0000715446

  • Non-accelerated filer
  • Smaller reporting company

Anixa Biosciences Inc

Sign in to watch
Ticker
ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Oct 31
Incorporated
DE
Entity type
Operating
EIN
112622630
Phone
+1 408-708-9808
Business address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Former names
ITUS Corp, COPYTELE INC
  1. 4 Open-market buy Director bought 87,700 shares at an average $0.16 ($14,391)
  2. 4 Open-market buy Director bought 70,000 shares at $0.15 ($10,430)
  3. 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($21,200)
  4. 4 Open-market buy Director bought 100,000 shares at an average $0.14 ($13,700)
  5. 4 Open-market buy President and CEO bought 30,000 shares at $0.14 ($4,269)
  6. 4 Open-market buy Director bought 50,000 shares at an average $0.16 ($8,140)
  7. 4 Open-market buy Director bought 30,000 shares at an average $0.15 ($4,440)
  8. 4 Open-market buy Director bought 10,000 shares at an average $0.16 ($1,612)
  9. 4 Open-market buy Director bought 206,544 shares at an average $0.15 ($30,076)
  10. 4 Open-market buy Director bought 10,000 shares at $0.13 ($1,270)
  11. 4 Open-market buy Director bought 155,000 shares at an average $0.14 ($21,173)
  12. 4 Open-market buy Director bought 245,000 shares at an average $0.10 ($25,220)
  13. 4 Open-market buy Director bought 223,325 shares at an average $0.11 ($23,909)
  14. 4 Open-market buy President and CEO bought 100,000 shares at an average $0.11 ($11,105)
  15. 4 Open-market buy Director bought 110,000 shares at $0.09 ($9,922)
  16. 4 Open-market buy Director bought 215,258 shares at $0.09 ($20,277)
  17. 4 Open-market buy Director bought 425,000 shares at an average $0.23 ($97,513)
  18. 4 Open-market buy Director bought 113,000 shares at $0.08 ($9,040)
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 16 of 24 · 471 filings